Volatile Valeant Substitutes Schiller For Ailing CEO

With investors growing increasingly edgy over the lingering absence of Valeant Pharmaceuticals International Inc.'s ailing chairman and CEO Michael Pearson – whose hospitalization late last month due to severe pneumonia came in the midst of the company's struggle to rebuild its image after being mired in a scandal over its business practices – the firm's board on Jan. 6 appointed former chief financial officer Howard Schiller to take the helm in the interim.

With investors growing increasingly edgy over the lingering absence of Valeant Pharmaceuticals International Inc.'s ailing chairman and CEO Michael Pearson – whose hospitalization late last month due to severe pneumonia came in the midst of the company's struggle to rebuild its image after being mired in a scandal over its business practices – the firm's board on Jan. 6 appointed former chief financial officer Howard Schiller to take the helm in the interim.

Investors were initially skittish on the news about Valeant's move to substitute Schiller for Pearson – pushing shares of the...

More from Dermatological

More from Therapy Areas

Compass Pathways’ Antidepressant Advances In An Increasingly Tough Psychedelic Market

 
• By 

Psychedelics appear to be in vogue after years of being relegated to alternative medicine. But investor pushback after the highly anticipated release of Phase III trial data by Compass Pathways reveals an increasingly high bar for development.

Eolo Pharma Advances In Obesity With Thermogenesis Approach

 
• By 

Emerging Company Profile: Early-stage biotech Eolo will seek cash and deals for its novel obesity drug SANA after positive Phase I results for weight loss, lean muscle mass preservation and fat mass reduction.

BioMarin’s Roctavian Continues to Shine In Hemophilia A Despite Commercial Woes

 

Roctavian shows durable bleed control and safety over five years, but high costs and access hurdles limit its commercial outlook.